On May 3, 2022 Fresenius Kabi reported that Bortezomib for Injection, an affordable treatment option for adult patients with multiple myeloma and mantle cell lymphoma in the United States and indicated for two routes of administration – intravenous and subcutaneous (Press release, Fresenius, MAY 3, 2022, View Source [SID1234613350]). This is the newest addition to the company’s expansive oncology portfolio in the United States.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!